Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Research
The Column Group biotech taps Surrozen to target lung fibrosis
TCGFB is paying Surrozen up to $6 million for antibodies that target transforming growth factor beta, a major contributor to lung diseases.
Darren Incorvaia
Nov 4, 2024 11:14am
Amgen disappears lung disease program after phase 2 fail
Oct 30, 2024 5:59pm
Novartis channels Gargamel, terminating midphase SMURF1 trial
Oct 14, 2024 9:14am
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
Sep 16, 2024 8:30am
Endeavor links IPF drug to improved lung function in phase 2
May 20, 2024 5:55am
Vicore's IPF drug improves lung function in phase 2 win
May 20, 2024 2:00am
